* Operating income increased 42 percent to $71.8 million, compared with $50.6million for the same period last year. Motesanibis part of a broad co-development program between Amgen and Takeda andMillennium: the Takeda Oncology Company.The Company also announced that Phase 2 programs in NSCLC in metastatic breastcancer have been completed The results support continued development. Thecompany will present detailed information in an appropriate scientific forum.Vectibix:The Company updated the status of the randomized, multicenter,Phase 3 study to compare the efficacy of panitumumab in combination withOxaliplatin/ 5-Fluorouracil/Leucovorin to the efficacy of Oxaliplatin/5-Fluorouracil/Leucovorin alone in patients with previously untreatedmetastatic colorectal cancer ('203 study). The review of the blinded dataavailable to date indicated that there had not been sufficient progressionevents to meet the minimum number as outlined in the statistical analysisplan. In addition, management has presented its outstanding debt inaccordance with GAAP and on an "adjusted" (or non-GAAP basis) at March 31,2009.The Company believes that the presentation of non-GAAP financialmeasures provides useful supplementary information to and facilitatesadditional analysis by investors.The Company uses these non-GAAP financialmeasures in connection with its own budgeting and financial planning.Thesenon-GAAP financial measures are in addition to, not a substitute for, orsuperior to, measures of financial performance prepared in conformity withGAAP.Forward-Looking StatementsThis news release contains forward-looking statements that involve significantrisks and uncertainties, including those discussed below and others that canbe found in our Form 10-K for the year ended Dec. APB 14-1,"Accounting for Convertible Debt Instruments That May Be Settledin Cash upon Conversion (Including Partial Cash Settlement)"("FSP APB 14-1").Amgen Inc.Notes to Reconciliation of GAAP Earnings to "Adjusted" Earnings(In millions, except per share data)(Unaudited) (a) Effective January 1, 2009, we adopted FSP APB 14-1, which changed the method of accounting for our convertible notes. In addition, as required, we revised our previously reported financial statements to retrospectively apply this change in accounting to prior periods.

Under this new method of accounting, the debt and equity components of our convertible notes are bifurcated and accounted for separately. The equity components of our convertible notes are included in Stockholders' equity in our Condensed Consolidated Balance Sheets with a corresponding reduction in the carrying values of our convertible notes as of the date of issuance or modification, as applicable.The reduced carrying values of our convertible notes are being accreted back to their principal amounts through the recognition of non-cash interest expense. This results in recognizing interest expense on these borrowings at effective rates approximating what we would have incurred had we issued nonconvertible debt with otherwise similar terms. In connection with applying this new accounting to prior periods, we recorded $57 million of additional non-cash interest expense in the three months ended March 31, 2008.

As a result, our previously reported results of operations calculated in accordance with GAAP have been revised for the three months ended March 31, 2008, as follows:Three months ended March 31, 2008--------------------------------------- As originallyEffect of FSP reported APB 14-1"Revised"---------------------------------------Operating income$1,415 $-$1,415Interest and other income (expense), net 22(57)(35) ------ ---Income before income taxes 1,437(57)1,380Provision for income taxes301(21)280 ------ ---Net income$1,136 $(36) $1,100====== ==========Earnings per share: Basic $1.04 $(0.03)$1.01 Diluted $1.04 $(0.03)$1.01 (b) To exclude the impact of stock option expense recorded in accordance with Statement of Financial Accounting Standards ("SFAS") No 123R. For the three months ended March 31, 2009 and 2008, the total pre-tax expense for employee stock options in accordance with SFAS No 123R was $24 million and $28 million, respectively. "Adjusted" diluted EPS including the impact of stock option expense for the three months ended March 31, 2009 and 2008 was as follows: Three months endedMarch 31,------------------20092008------------------"Adjusted" diluted EPS, excluding stock option expense$1.08 $1.12Impact of stock option expense (net of tax)(0.01)(0.02) ----- -----"Adjusted" diluted EPS, including stock option expense$1.07 $1.10 ===== ===== (c) To exclude the ongoing, non-cash amortization of the R&D technology intangible assets acquired with the acquisitions of Abgenix, Inc ("Abgenix") and Avidia, Inc ("Avidia"). (e) To exclude the ongoing, non-cash amortization of acquired product technology rights, primarily ENBREL, related to the Immunex Corporation ("Immunex") acquisition. (f) To exclude the incremental non-cash interest expense resulting from our adoption of FSP APB 14-1 (see (a) above). (g) To exclude merger related expenses incurred due to the Alantos Pharmaceutical Holding, Inc.

acquisition, primarily related to incremental costs associated with retention. (h) To reflect the tax effect of the above adjustments for 2009. (i) To exclude the net tax benefit resulting from adjustments to previously established deferred taxes, primarily related to prior acquisitions and stock option expense, due to changes in California tax law effective for future periods. (j) To reflect the tax effect of the above adjustments for 2008, excluding certain of the restructuring charges (see (d) above). (k) The following table presents the computations for GAAP and "Adjusted" diluted earnings per share, computed under the treasury stock method.

123R.Amgen Inc.Product Sales Detail by Product and Geographic Region(In millions)(Unaudited) Three months endedMarch 31, ----------------------- 2009 2008 -----------------------Aranesp(R) - U.S.$292 $405Aranesp(R) - International334356EPOGEN(R) - U.S.565554Neulasta(R) - U.S.594569NEUPOGEN(R) - U.S.202223Neulasta(R) - International 183187NEUPOGEN(R) - International94107Enbrel(R) - U.S.712904Enbrel(R) - International46 47Sensipar(R) - U.S 99 93Sensipar(R) - International49 40Vectibix(R) - U.S. 25 32Vectibix(R) - International282Other product sales - U.S. 138Other product sales - International 2 10------Total product sales$3,238 $3,537 ====== ======U.S. In addition, as required, we revised ourpreviously reported financial statements to retrospectively applythis change in accounting to prior periods. 123R.(e) To exclude restructuring related costs.(f) To exclude the ongoing, non-cash amortization of the R&D technologyintangible assets acquired with the Abgenix and Avidia acquisitions.(g) To exclude the net tax benefit resulting from adjustments topreviously established deferred taxes, primarily related to prioracquisitions and stock option expense, due to changes in Californiatax law effective for future periods.CONTACT: Amgen, Thousand Oaks David Polk, 805-447-4613 (media) Arvind Sood, 805-447-1060 (investors)(Logo: http://)SOURCEAmgenmedia, David Polk, +1-805-447-4613, or investors, Arvind Sood,+1-805-447-1060, both of Amgen. Video via user SCkego on YouTube and mothcontrol /sc.Sometimes you have to look to the past to get a glimpse of things to come So here's your glimpse New Years Day, 1975 The granddaddy of them all: The Rose Bowl No 4 USC clinched the Pac-8 to face No.